{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:51:29Z","timestamp":1788411089061,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eprac.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:05:35Z","timestamp":1750169135000},"page":"1319-1328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Thyroid Eye Disease: Management, Advances, and Future Opportunities"],"prefix":"10.1016","volume":"31","author":[{"given":"Tamaryn","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Lora","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-5135","authenticated-orcid":false,"given":"Chrysoula","family":"Dosiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6S","key":"10.1016\/j.eprac.2025.06.011_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid eye disease: epidemiology, natural history, and risk factors","volume":"39","author":"Bartalena","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.011_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jamaophthalmol.2022.1002","article-title":"Nationwide incidence of thyroid eye disease and cumulative incidence of strabismus and surgical interventions in Denmark","volume":"140","author":"Boulakh","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.011_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib4","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1089\/thy.2024.0304","article-title":"The epidemiology of thyroid eye disease in Olmsted county, Minnesota, 2005\u20132020","volume":"34","author":"Rachmasari","year":"2024","journal-title":"Thyroid\u00ae"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.011_bib6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41433-024-02967-9","article-title":"The changing landscape of thyroid eye disease: current clinical advances and future outlook","volume":"38","author":"Moledina","year":"2024","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2014.0475","article-title":"Role of the underlying thyroid disease on the phenotype of graves\u2019 orbitopathy in a tertiary referral center","volume":"25","author":"Leo","year":"2015","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40618-019-01141-3","article-title":"Orbital diseases mimicking graves\u2019 orbitopathy: a long-standing challenge in differential diagnosis","volume":"43","author":"Marin\u00f2","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.011_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/138920211798120844","article-title":"Graves ophthalmopathy: a review of immunogenetics","volume":"12","author":"Khalilzadeh","year":"2011","journal-title":"CG"},{"key":"10.1016\/j.eprac.2025.06.011_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajo.2023.01.020","article-title":"Smoking is associated with a higher risk of surgical intervention for thyroid eye disease in the IRIS registry","volume":"249","author":"Oke","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/IOP.0000000000002770","article-title":"Effect of Cannabis usage on thyroid eye disease","volume":"41","author":"Zong","year":"2025","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib12","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0133","article-title":"The relationship between cholesterol levels and thyroid eye disease","volume":"14","author":"Cardo","year":"2025","journal-title":"Eur Thyroid J"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12886-024-03824-9","article-title":"Association of obesity with orbital fat expansion in thyroid eye disease","volume":"25","author":"Kuo","year":"2025","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/IOP.0000000000001437","article-title":"Serum vitamin D deficiency is an independent risk factor for thyroid eye disease","volume":"36","author":"Heisel","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib15","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.4103\/IJO.IJO_912_23","article-title":"Assessment of risk of obstructive sleep apnea with thyroid eye disease and its activity","volume":"71","author":"Kumari","year":"2023","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.011_bib17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib18","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.011_bib105","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0161-6420(88)32978-7","article-title":"Dysthyroid optic neuropathy. The crowded orbital apex syndrome","volume":"95","author":"Neigel","year":"1988","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.011_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/cen.15128","article-title":"The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves\u2019 orbitopathy: a systematic review and meta-analysis of randomised controlled trials","volume":"101","author":"Sharabati","year":"2024","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib20","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"issue":"Suppl_1","key":"10.1016\/j.eprac.2025.06.011_bib21","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","article-title":"Teprotumumab and the evolving therapeutic landscape in thyroid eye disease","volume":"107","author":"Kossler","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.06.011_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820958335","article-title":"Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application","volume":"11","author":"L\u00e4ngericht","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.011_bib23","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib24","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"32","key":"10.1016\/j.eprac.2025.06.011_bib25","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1002213107","article-title":"Inducible response required for repair of low-dose radiation damage in human fibroblasts","volume":"107","author":"Grudzenski","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.011_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/ICU.0b013e3283560b2b","article-title":"Orbital radiotherapy for thyroid eye disease","volume":"23","author":"Dolman","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ophtha.2021.10.025","article-title":"Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology","volume":"129","author":"Sobel","year":"2022","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.011_bib28","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1210\/jc.2012-2758","article-title":"Efficacy and safety of orbital radiotherapy for graves\u2019 orbitopathy","volume":"97","author":"Tanda","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"The Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.011_bib30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","article-title":"Sirolimus as a second-line treatment for Graves\u2019 orbitopathy","volume":"45","author":"Lanzolla","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40618-024-02470-8","article-title":"Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus","volume":"48","author":"Comi","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.011_bib32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.011_bib35","article-title":"Tocilizumab for thyroid eye disease","volume":"11","author":"Hamed Azzam","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2025.06.011_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.011_bib37","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory graves\u2019 orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"JCM"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.011_bib38","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/thy.2023.0167","article-title":"Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease","volume":"33","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid\u00ae"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10792-024-03117-6","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study","volume":"44","author":"Lee","year":"2024","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.eprac.2025.06.011_bib40","article-title":"The efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis","author":"Sun","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: measure, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and Re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/IOP.0000000000001003","article-title":"Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy","volume":"34","author":"Gold","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/WNO.0000000000001994","article-title":"Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy","volume":"44","author":"Tamhankar","year":"2024","journal-title":"J Neuro-Ophthalmology"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10792-024-03143-4","article-title":"Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort","volume":"44","author":"Habroosh","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.011_bib47","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/jpm14070776","article-title":"Thyroid eye disease: advancements in orbital and ocular pathology management","volume":"14","author":"Scarabosio","year":"2024","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101773","article-title":"Chemokines in thyroid autoimmunity","volume":"37","author":"Ferrari","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib49","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1210\/clinem\/dgae339","article-title":"PAPP-A as a potential target in thyroid eye disease","volume":"109","author":"Conover","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.06.011_bib50","article-title":"CD34+ orbital fibroblasts contribute to the pathogenesis of thyroid eye disease via miR-182-5p","author":"Yu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/iovs.65.2.25","article-title":"SOX9 induces orbital fibroblast activation in thyroid eye disease via MAPK\/ERK1\/2 pathway","volume":"65","author":"Zhou","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib52","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1089\/thy.2023.0309","article-title":"Yes-associated protein mediates the transition from inflammation to fibrosis in graves\u2019 orbitopathy","volume":"33","author":"Ko","year":"2023","journal-title":"Thyroid\u00ae"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib53","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1210\/clinem\/dgaa959","article-title":"Slit2 regulation of hyaluronan and cytokine synthesis in fibrocytes in thyroid-associated ophthalmopathy","volume":"106","author":"Antonelli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib54","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1210\/clinem\/dgaa684","article-title":"Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: potential relevance to thyroid-associated ophthalmopathy","volume":"106","author":"Fernando","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.06.011_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae899","article-title":"Stimulation of Piezo1 mechanosensitive channels inhibits adipogenesis in thyroid eye disease","author":"Galgoczi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.survophthal.2023.01.003","article-title":"Orbital and ocular perfusion in thyroid eye disease","volume":"68","author":"Goel","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41598-023-27483-w","article-title":"Serum microRNA as a potential biomarker for the activity of thyroid eye disease","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35096-x","article-title":"Tear proteins calcium binding protein A4 (S100A4) and prolactin induced protein (PIP) are potential biomarkers for thyroid eye disease","volume":"8","author":"Chng","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib59","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/ijms22031115","article-title":"Tear-derived exosome proteins are increased in patients with thyroid eye disease","volume":"22","author":"Han","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.eprac.2025.06.011_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1356055","article-title":"Advances in artificial intelligence in thyroid-associated ophthalmopathy","volume":"15","author":"Yi","year":"2024","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12902-021-00895-3","article-title":"Quantitative evaluation of activity of thyroid-associated ophthalmopathy using short-tau inversion recovery (STIR) sequence","volume":"21","author":"Ge","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.011_bib62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.65.5.6","article-title":"Deep-learning based automated segmentation and quantitative volumetric analysis of orbital muscle and fat for diagnosis of thyroid eye disease","volume":"65","author":"Alkhadrawi","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.eprac.2025.06.011_bib63","article-title":"Clinical and radiologic predictors of response to teprotumumab: a 3D volumetric analysis of 35 patients","author":"Ugradar","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib64","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1089\/thy.2022.0172","article-title":"A survey on the management of thyroid eye disease among American and European thyroid association members","volume":"32","author":"Brito","year":"2022","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.011_bib65","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.eprac.2024.06.010","article-title":"Impact of teprotumumab on clinical practice in thyroid eye disease","volume":"30","author":"Rachmasari","year":"2024","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib66","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/IOP.0000000000002564","article-title":"Teprotumumab for the treatment of recalcitrant thyroid eye disease","volume":"40","author":"Men","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/WNO.0000000000002001","article-title":"Objective diplopia outcomes for patients treated with teprotumumab for thyroid eye disease","volume":"44","author":"Mudalegundi","year":"2024","journal-title":"J Neuro-Ophthalmology"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib68","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/IOP.0000000000002611","article-title":"Teprotumumab for thyroid eye disease-related strabismus","volume":"40","author":"Dallalzadeh","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.011_bib69","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib71","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.06.011_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eprac.2025.06.011_bib73","article-title":"Patterns of teprotumumab-induced hearing dysfunction: a systematic review","author":"Wong","year":"2024","journal-title":"Otolaryngol--Head Neck Surg"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib75","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/thy.2023.0466","article-title":"A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease","volume":"34","author":"Douglas","year":"2024","journal-title":"Thyroid\u00ae"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.011_bib76","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-related adverse events in thyroid eye disease: a multicenter study","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib77","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/IOP.0000000000002569","article-title":"Menstrual irregularities and amenorrhea in thyroid eye disease patients treated with teprotumumab","volume":"40","author":"Terrarosa","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.011_bib78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2025.06.011_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/WNO.0000000000002280","article-title":"Observational characterization of the retreatment course of patients with thyroid eye disease","author":"Chen","year":"2025","journal-title":"J Neuro-Ophthalmology"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib80","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ophtha.2024.07.018","article-title":"The rate of Re-treatment in patients treated with teprotumumab","volume":"132","author":"Ugradar","year":"2025","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/IOP.0000000000002531","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.eprac.2025.06.011_bib82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.011_bib83","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/IOP.0000000000001630","article-title":"Stereotactic navigation improves outcomes of orbital decompression surgery for thyroid associated orbitopathy","volume":"36","author":"Heisel","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib84","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/IOP.0b013e3181b8e614","article-title":"Ultrasonic bone removal versus high-speed burring for lateral orbital decompression: comparison of surgical outcomes for the treatment of thyroid eye disease","volume":"26","author":"Cho","year":"2010","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/tjo.tjo_57_21","article-title":"Management of eyelid retraction related to thyroid eye disease","volume":"12","author":"Osaki","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"issue":"17_supplement_2","key":"10.1016\/j.eprac.2025.06.011_bib86","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1212\/WNL.0000000000202314","article-title":"Phase 1\/2 clinical study of VRDN-001, A full antagonist antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with thyroid eye disease (TED) (P3-9.001)","volume":"100","author":"Moster","year":"2023","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.011_bib87","first-page":"3995","article-title":"VRDN-002, A second-generation insulin like growth factor-1 receptor (IGF-1R) inhibitory antibody for thyroid eye disease: preclinical pharmacokinetics and clinical promise","volume":"63","author":"Dickinson","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.06.011_bib88","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.1891","article-title":"FRI546 VRDN-001, A full antagonist antibody to IGF-1 receptor in development for thyroid eye disease (TED): pharmacodynamic responses in healthy volunteers and patients with active TED","volume":"7","author":"Foster","year":"2023","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.011_bib89","first-page":"4043","article-title":"Preclinical pharmacokinetics of VRDN-003, A next-generation half-life extended antibody to the IGF-1 receptor for thyroid eye disease","volume":"64","author":"Dickinson","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.eprac.2025.06.011_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1211473","article-title":"Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease","volume":"14","author":"Gulbins","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.011_bib91","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.011_bib92","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy-Results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of graves\u2019 orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib94","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.eprac.2025.06.011_bib95","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fendo.2016.00130","article-title":"TSH receptor signaling abrogation by a novel small molecule","volume":"7","author":"Latif","year":"2016","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.011_bib96","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/thy.2022.0694","article-title":"Thyrotropin receptor antagonism by a novel small molecule: preclinical in vitro observations","volume":"33","author":"Kahaly","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2025.06.011_bib97","article-title":"2\u2032-O-Galloylhyperin prevents tissue remodeling in thyroid eye disease: prospects as a thyrotropin receptor antagonist","author":"Guo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.011_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28397","article-title":"Comparison of orbital fibroblasts from Graves\u2019 ophthalmopathy and healthy control","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.011_bib99","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad004","article-title":"Looking beyond Th17 cells: a role for Th17.1 cells in thyroid-associated ophthalmopathy?","volume":"164","author":"Jiang","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.eprac.2025.06.011_bib100","article-title":"Automatic measurement of exophthalmos based orbital CT images using deep learning","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.011_bib101","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11548-020-02281-1","article-title":"Artificial intelligence CT screening model for thyroid-associated ophthalmopathy and tests under clinical conditions","volume":"16","author":"Song","year":"2021","journal-title":"Int J CARS"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00417-023-06256-1","article-title":"Use of extreme gradient boosting, light gradient boosting machine, and deep neural networks to evaluate the activity stage of extraocular muscles in thyroid-associated ophthalmopathy","volume":"262","author":"Li","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100412","article-title":"A deep learning model for screening computed tomography imaging for thyroid eye disease and compressive optic neuropathy","volume":"4","author":"Lin","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.011_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25887-8","article-title":"Machine learning-assisted system using digital facial images to predict the clinical activity score in thyroid-associated orbitopathy","volume":"12","author":"Moon","year":"2022","journal-title":"Sci Rep"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:44:40Z","timestamp":1759301080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1530891X25009267"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.06.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Eye Disease: Management, Advances, and Future Opportunities","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}